Why can't I lose weight on Mounjaro? Common reasons and what to do

Is the dose simply too low to produce noticeable change yet?

This is the most common reason people feel Mounjaro isn't working, and it's worth saying plainly: the 2.5 mg starting pen exists to settle your system into the medicine, not to produce the weight loss you'll eventually see. Most people don't notice significant appetite suppression until 5 mg or beyond. The titration schedule is typically stepped up every four weeks by the prescriber, which means it can take two to three months before you're at a dose that meaningfully changes how much you want to eat.

If you're in the first couple of months and your weight hasn't moved much, that's often exactly what the clinical data predicts. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average reductions of around 20–21% at the 15 mg maintenance dose over 72 weeks, that's not a result the first pen delivers. The trajectory matters more than the number on the scales this month. A note our prescribers hear regularly: people pull the pen from the fridge door, inject on day one, and expect the same experience at week two that others describe at week forty. The medicine doesn't work that way.

Talk to your prescriber before changing anything. If you feel your titration has stalled, there may be a clinical reason (such as tolerability) and that's a conversation worth having through your clinical team rather than stopping unilaterally. It's also worth reading about why some people can't get Mounjaro in the first place, as eligibility and access issues can affect whether you're getting the right dose or the medicine at all.

Could something in your routine be working against the medicine?

Mounjaro reduces appetite, but it doesn't eliminate the effect of what you eat when you do eat. A smaller portion of calorie-dense food can still outweigh what the medicine does to hunger. The most common patterns that undermine progress are: liquid calories that bypass fullness signals (alcohol, sweetened drinks, soups and smoothies pass through the stomach faster than solid food); irregular meals that lead to reactive overeating when hunger does return; and inadequate protein, which matters more than usual because tirzepatide-related weight loss includes some lean mass alongside fat.

Sleep is genuinely underrated here. Poor sleep disrupts ghrelin and leptin (the hormones that regulate hunger) and can blunt the medicine's effect on appetite. Stress has a similar impact. None of this is a failure of willpower; it's physiology. The NHS tirzepatide guidance notes that the medicine works best alongside a reduced-calorie diet and increased physical activity, and that's not just boilerplate, the clinical trials were run with lifestyle support in place.

For practical ideas on adjusting your approach while on treatment, the guide on getting the most from Mounjaro covers this in more detail. Small, sustainable changes usually outperform drastic ones.

What if the medicine genuinely isn't working for you?

A small proportion of people respond less well to tirzepatide than trial averages suggest, and that's real. Individual variation in how quickly the stomach empties, gut-hormone receptor sensitivity, and metabolic baseline all play a role. If you've been at your highest tolerated dose for at least three to four months and weight loss remains minimal, that's when a prescriber needs to reassess the full picture, other medical factors, including thyroid function or medications that cause weight gain, may need investigating.

NICE's appraisal of tirzepatide (TA1026) recommends reviewing continuation if someone achieves less than 5% weight loss after six months at their highest tolerated dose. That's a clinical checkpoint, not an automatic stop. There may be dose adjustments still available, a switch to consider, or a reason the response has been limited that a prescriber can identify. This is also why the question of whether some people simply don't respond to Mounjaro deserves a thorough answer of its own.

If you haven't yet started and are weighing up whether tirzepatide is the right option for you, the evidence on individual results may help frame realistic expectations before you begin. And if slow progress is something you're already navigating, the dedicated page on that specific experience goes into more detail.

When should you actively involve your prescriber?

There's a difference between a natural plateau and a signal that something needs clinical attention. Speak to your prescriber if: your weight hasn't changed in eight or more weeks despite being at the same dose for long enough; you're experiencing side effects that are making it harder to eat adequately; you've noticed symptoms such as severe stomach pain, significant nausea that isn't improving, or anything that worries you. Side effects are common at the start or after a dose step (typically GI symptoms like nausea, loose stools, or constipation) and usually settle within a couple of weeks. But persistent or severe symptoms, particularly severe abdominal pain that spreads to the back, need urgent medical attention.

At nume, every repeat order is clinically reviewed before it's dispensed, there's no auto-renewal, no algorithm waving you through. If progress has stalled, that review is a natural point to raise it. You can also reach the aftercare team via the contact page, seven days a week. The question of how the medicine actually produces weight loss can also help you understand what to look for as a sign the mechanism is working, even if the scales are slow to move. And if you're still deciding whether to begin treatment, exploring your options with a free consultation is the right first step.